Evidence map›Paper›PMID 32952337›Full record

ArticleWorld journal of gastroenterology2020

Treatment repurposing for inflammatory bowel disease using literature-related discovery and innovation.

Ronald Neil Kostoff, Michael Brandon Briggs, Darla Roye Shores

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Modifiable contributing factors to COVID-19: A comprehensive review.Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association · 2023
    Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ronald Neil KostoffSchool of Public Policy, Georgia Institute of Technology, Gainesville, VA 20155, United States. ronald.kostoff@pubpolicy.gatech.edu.
Michael Brandon BriggsIndependent Consultant, Roscommon, MI 48653, United States.
Darla Roye ShoresThe Hopkins Resource for Intestinal Vitality and Enhancement, the Johns Hopkins University School of Medicine, Baltimore, MD 21287, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammatory bowel disease (IBD) incidence has been increasing steadily, most dramatically in the Western developed countries. Treatment often includes lifelong immunosuppressive therapy and surgery. There is a critical need to reduce the burden of IBD and to discover medical therapies with better efficacy and fewer potential side-effects. Repurposing of treatments originally studied in other diseases with similar pathogenesis is less costly and time intensive than de novo drug discovery. This study used a treatment repurposing methodology, the literature-related discovery and innovation (LRDI) text mining system, to identify potential treatments (developed for non-IBD diseases) with sufficient promise for extrapolation to treatment of IBD. By searching for desirable patterns of twenty key biomarkers relevant to IBD (

Indexed as

ColitisColitis, UlcerativeCrohn DiseaseInflammatory Bowel DiseasesAnimalsDrug RepositioningHumansCrohn’s diseaseInflammatory bowel diseaseLiterature-based discoveryNovel treatmentsText miningTreatment repositioningTreatment repurposingUlcerative colitis

Identifiers

PMID32952337
PMCPMC7476176

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.